A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily, With the Dose Chosen According to Blood Pressure at Enrollment as in Routine Practice, Over 9 Months in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.
Key facts
- Who runs it
- Tri-Service General Hospital (TSGH)
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 26 Oct 2022
- Ended
- 16 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Olmesartan
- Record updated
- 17 November 2026
Who can take part
- Age
- 20 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adults with type 2 diabetes mellitus. Patients receiving ongoing sodium-glucose cotransporter-2 inhibitor therapy. Patients with persistent albuminuria who meet the study-defined eligibility criteria
- Patients who are willing and able to provide written informed consent
Who cannot take part
- Known hypersensitivity or history of severe adverse reactions to other angiotensin receptor blockers (ARBs)
- Active liver disease or severe hepatic impairment (Aspartate transaminase [AST] > 3 × ULN [upper limit of normal]; Alanine transaminase [ALT] > 3 × ULN)
- Moderate-to-severe renal impairment (estimated GFR < 30 mL/min/1.73 m²). Women who are pregnant or currently breastfeeding. Judged by the study investigator to be unsuitable for participating (or continuing) in this trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluates the efficacy and safety of adding olmesartan to sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in patients with type 2 diabetes mellitus and persistent albuminuria. Participants receive olmesartan at a dose of either 20 mg or 40 mg daily in addition to their ongoing SGLT2i treatment. Changes in urinary albumin-to-creatinine ratio (UACR), renal function, and blood pressure are assessed over a 9-month follow-up period. The study aims to evaluate the potential additional renoprotective effects of olmesartan in patients with type 2 diabetes who continue to have albuminuria despite SGLT2i therapy.
The 2 groups in the trial
- Olmesartan 20 mgExisting treatment, for comparison
Participants receive olmesartan 20 mg orally once daily in addition to their ongoing SGLT2 inhibitor therapy.
Treatment: Olmesartan
- Olmesartan 40 mgTreatment being tested
Description: Participants receive olmesartan 40 mg orally once daily in addition to their ongoing SGLT2 inhibitor therapy.
Treatment: Olmesartan
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- TSGHIRB No:A202205147。A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.
- Record updated
- 17 November 2026